• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

澳大利亚和新西兰局部侵袭性(T4)直肠癌治疗和结局的地域差异:双国家结直肠癌审计分析。

Regional variance in treatment and outcomes of locally invasive (T4) rectal cancer in Australia and New Zealand: analysis of the Bi-National Colorectal Cancer Audit.

机构信息

Colorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

Faculty of Medical Sciences, Utrecht University, Utrecht, The Netherlands.

出版信息

ANZ J Surg. 2022 Jul;92(7-8):1772-1780. doi: 10.1111/ans.17699. Epub 2022 May 3.

DOI:10.1111/ans.17699
PMID:35502647
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9541368/
Abstract

BACKGROUNDS

Locally invasive T4 rectal cancer often requires neoadjuvant treatment followed by multi-visceral surgery to achieve a radical resection (R0), and referral to a specialized exenteration quaternary centre is typically recommended. The aim of this study was to explore regional variance in treatment and outcomes of patients with locally advanced rectal cancer in Australia and New Zealand (ANZ).

METHODS

Data were collected from the Bi-National Colorectal Cancer Audit (BCCA) database. Rectal cancer patients treated between 2007 and 2019 were divided into six groups based on region (state/country) using patient postcode. A subset analysis of patients with T4 cancer was performed. Primary outcomes were positive circumferential resection margin (CRM+), and positive circumferential and/or distal resection margin (CRM/DRM+).

RESULTS

A total of 9385 patients with rectal cancer were identified, with an overall CRM+ rate of 6.4% and CRM/DRM+ rate of 8.6%. There were 1350 patients with T4 rectal cancer (14.4%). For these patients, CRM+ rate was 18.5%, and CRM/DRM+ rate was 24.1%. Significant regional variation in CRM+ (range 13.4-26.0%; p = 0.025) and CRM/DRM+ rates (range 16.1-29.3%; p = 0.005) was identified. In addition, regions with higher CRM+ and CRM/DRM+ rates reported lower rates of multi-visceral resections: range 24.3-26.8%, versus 32.6-37.3% for regions with lower CRM+ and CRM/DRM+ rates (p < 0.0001).

CONCLUSION

Positive resection margins and rates of multi-visceral resection vary between the different regions of ANZ. A small subset of patients with T4 rectal cancer are particularly at risk, further supporting the concept of referral to specialized exenteration centres for potentially curative multi-visceral resection.

摘要

背景

局部侵袭性 T4 直肠肿瘤常需要新辅助治疗,然后进行多脏器手术以实现根治性切除(R0),通常建议转至专门的根治性切除术四级中心。本研究旨在探讨澳大利亚和新西兰(ANZ)局部晚期直肠肿瘤患者的治疗和结局的区域差异。

方法

从双国家结直肠癌审计(BCCA)数据库中收集数据。根据患者邮政编码,将 2007 年至 2019 年期间治疗的直肠肿瘤患者分为六个组,按区域(州/国家)划分。对 T4 癌症患者进行了亚组分析。主要结局是阳性环周切缘(CRM+)和阳性环周及/或远端切缘(CRM/DRM+)。

结果

共确定了 9385 例直肠肿瘤患者,总体 CRM+率为 6.4%,CRM/DRM+率为 8.6%。有 1350 例 T4 直肠肿瘤患者(14.4%)。这些患者的 CRM+率为 18.5%,CRM/DRM+率为 24.1%。CRM+(范围 13.4-26.0%;p=0.025)和 CRM/DRM+(范围 16.1-29.3%;p=0.005)率存在显著的区域差异。此外,CRM+和 CRM/DRM+率较高的区域报告的多脏器切除术比例较低:范围为 24.3-26.8%,而 CRM+和 CRM/DRM+率较低的区域为 32.6-37.3%(p<0.0001)。

结论

ANZ 不同地区的切缘阳性率和多脏器切除术率存在差异。一小部分 T4 直肠肿瘤患者风险特别高,进一步支持转至专门的根治性切除术中心进行潜在治愈性多脏器切除术的概念。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d91/9541368/bdaaff001cdd/ANS-92-1772-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d91/9541368/bdaaff001cdd/ANS-92-1772-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d91/9541368/bdaaff001cdd/ANS-92-1772-g002.jpg

相似文献

1
Regional variance in treatment and outcomes of locally invasive (T4) rectal cancer in Australia and New Zealand: analysis of the Bi-National Colorectal Cancer Audit.澳大利亚和新西兰局部侵袭性(T4)直肠癌治疗和结局的地域差异:双国家结直肠癌审计分析。
ANZ J Surg. 2022 Jul;92(7-8):1772-1780. doi: 10.1111/ans.17699. Epub 2022 May 3.
2
The influence of circumferential resection margins on survival following rectal cancer surgery.直肠癌手术后环周切缘对生存的影响。
Ann Ital Chir. 2017;88.
3
Positive Circumferential Resection Margin in Rectal Cancer Is a Robust Predictor of Poor Long-term Prognosis With Clinicopathological Bias Between Groups Compensated by Propensity-score Matching Analysis.直肠癌环周切缘阳性是预后不良的有力预测指标,通过倾向评分匹配分析可以在一定程度上弥补组间临床病理偏倚。
Anticancer Res. 2023 Aug;43(8):3623-3630. doi: 10.21873/anticanres.16542.
4
Circumferential margin involvement after total mesorectal excision for mid or low rectal cancer: are all R1 resections equal?直肠系膜全切除术后中低位直肠癌环周切缘受累:所有 R1 切除都是相等的吗?
Colorectal Dis. 2017 Nov;19(11):O377-O385. doi: 10.1111/codi.13895.
5
Management of the positive pathologic circumferential resection margin in rectal cancer: A national cancer database (NCDB) study.直肠癌阳性病理环周切缘的管理:国家癌症数据库(NCDB)研究。
Eur J Surg Oncol. 2021 Feb;47(2):296-303. doi: 10.1016/j.ejso.2020.07.033. Epub 2020 Aug 1.
6
The minimum distal resection margin in rectal cancer surgery and its impact on local recurrence - A retrospective cohort analysis.直肠癌手术的最小远端切缘及其对局部复发的影响-回顾性队列分析。
Int J Surg. 2019 Sep;69:77-83. doi: 10.1016/j.ijsu.2019.07.029. Epub 2019 Jul 27.
7
Outcomes of Minimally Invasive Versus Open Proctectomy for Rectal Cancer: A Propensity-Matched Analysis of Bi-National Colorectal Cancer Audit Data.微创与开放直肠切除术治疗直肠癌的结果:基于两国结直肠癌症审核数据的倾向评分匹配分析。
Dis Colon Rectum. 2020 Jun;63(6):778-787. doi: 10.1097/DCR.0000000000001654.
8
Importance of surgical margins in rectal cancer.手术切缘在直肠癌中的重要性。
J Surg Oncol. 2016 Mar;113(3):323-32. doi: 10.1002/jso.24136.
9
Abdominoperineal excision in Australasia: clinical outcomes, predictive factors and recent trends of nonrestorative rectal cancer surgery.澳大利亚和亚洲地区的腹会阴联合切除术:非修复性直肠癌手术的临床结果、预测因素和近期趋势。
Colorectal Dis. 2020 Nov;22(11):1614-1625. doi: 10.1111/codi.15263. Epub 2020 Aug 8.
10
International evaluation of circumferential resection margins after rectal cancer resection: insights from the Swedish and Dutch audits.直肠癌切除术后环周切缘评估的国际评价:来自瑞典和荷兰审计的见解。
Colorectal Dis. 2020 Apr;22(4):416-429. doi: 10.1111/codi.14903. Epub 2019 Nov 27.

引用本文的文献

1
Minimally invasive surgery for maximally invasive tumors-pelvic exenterations for rectal cancers: are we prepared?针对侵袭性最强的肿瘤进行微创手术——直肠癌盆腔脏器切除术:我们准备好了吗?
J Minim Invasive Surg. 2022 Dec 15;25(4):127-128. doi: 10.7602/jmis.2022.25.4.127.

本文引用的文献

1
Persistent High Rate of Positive Margins and Postoperative Complications After Surgery for cT4 Rectal Cancer at a National Level.全国范围内 cT4 期直肠癌手术后切缘阳性率和术后并发症持续居高不下。
Dis Colon Rectum. 2021 Apr 1;64(4):389-398. doi: 10.1097/DCR.0000000000001855.
2
Multivisceral Resection of Advanced Pelvic Tumors: From Planning to Implementation.晚期盆腔肿瘤的多脏器切除术:从规划到实施
Clin Colon Rectal Surg. 2020 Sep;33(5):268-278. doi: 10.1055/s-0040-1713744. Epub 2020 Sep 18.
3
Total neoadjuvant therapy for rectal cancer: here and now.
直肠癌的全新辅助治疗:现状与进展
ANZ J Surg. 2021 Jan;91(1-2):12-13. doi: 10.1111/ans.16153. Epub 2020 Aug 28.
4
Referral patterns and outcomes of a highly specialised pelvic exenteration multidisciplinary team meeting: A retrospective cohort study.高度专业化的盆腔廓清术多学科团队会议的转诊模式和结果:一项回顾性队列研究。
Eur J Surg Oncol. 2020 Jun;46(6):1138-1143. doi: 10.1016/j.ejso.2020.02.031. Epub 2020 Feb 21.
5
State-wide outcomes in elective rectal cancer resection: is there a case for centralization in Victoria?全州范围内择期直肠癌切除术的结果:维多利亚州是否有集中化的理由?
ANZ J Surg. 2019 Dec;89(12):1642-1646. doi: 10.1111/ans.15546. Epub 2019 Dec 4.
6
Hospital surgical volume and perioperative mortality of pelvic exenteration for gynecologic malignancies.妇科恶性肿瘤盆腔脏器清除术的医院手术量与围手术期死亡率
J Surg Oncol. 2020 Feb;121(2):402-409. doi: 10.1002/jso.25770. Epub 2019 Nov 19.
7
Neoadjuvant radiotherapy for rectal cancer management.直肠癌新辅助放疗管理。
World J Gastroenterol. 2019 Sep 7;25(33):4850-4869. doi: 10.3748/wjg.v25.i33.4850.
8
Pushing the boundaries of pelvic exenteration by maintaining survival at the cost of morbidity.以增加发病率为代价,维持生存,从而扩大盆腔廓清术的边界。
Br J Surg. 2019 Sep;106(10):1393-1403. doi: 10.1002/bjs.11203. Epub 2019 Jul 8.
9
Short- and long-term outcomes of selective pelvic exenteration surgery in a low-volume specialized tertiary setting.
ANZ J Surg. 2019 Jun;89(6):E226-E230. doi: 10.1111/ans.15212. Epub 2019 May 8.
10
Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy.新辅助治疗后完全缓解的直肠癌患者采用观察等待策略的评估。
JAMA Oncol. 2019 Apr 1;5(4):e185896. doi: 10.1001/jamaoncol.2018.5896. Epub 2019 Apr 11.